JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Начало・Списък с акции・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

40.96 -2.17

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

40.64

Максимум

42.05

Ключови измерители
By Trading Economics
Приходи	-6.2M -91M
Марж на печалбата	-867.293
Служители	316
EBITDA	4M -90M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+30.49% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-27M 3.2B
Предишно отваряне	43.13
Предишно затваряне	40.96

Настроения в новините

By Acuity

50%

152 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

34.81 / 38.24 Подкрепа & съпротива

Xenon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.02.2026 г., 23:11 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Decline After Hitting All-Time High -- Market Talk

3.02.2026 г., 23:42 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Technical Correction -- Market Talk

3.02.2026 г., 23:41 ч. UTC

Придобивния, сливания и поглъщания

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3.02.2026 г., 23:38 ч. UTC

Печалби

AMD Sales Climb on Help From Data-Center Business -- Update

3.02.2026 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3.02.2026 г., 23:27 ч. UTC

Придобивния, сливания и поглъщания

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3.02.2026 г., 23:25 ч. UTC

Придобивния, сливания и поглъщания

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3.02.2026 г., 23:23 ч. UTC

Придобивния, сливания и поглъщания

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3.02.2026 г., 23:22 ч. UTC

Придобивния, сливания и поглъщания

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3.02.2026 г., 23:19 ч. UTC

Пазарно говорене

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3.02.2026 г., 23:19 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

3.02.2026 г., 22:56 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3.02.2026 г., 22:40 ч. UTC

Печалби

Amdocs Extends Collaboration With T-Mobile

3.02.2026 г., 22:39 ч. UTC

Печалби

Amdocs 1Q Adj EPS $1.81

3.02.2026 г., 22:39 ч. UTC

Печалби

Amdocs 1Q Rev $1.16B

3.02.2026 г., 22:39 ч. UTC

Печалби

Amdocs 1Q EPS $1.45 >

3.02.2026 г., 22:38 ч. UTC

Печалби

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3.02.2026 г., 22:30 ч. UTC

Придобивния, сливания и поглъщания

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3.02.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3.02.2026 г., 22:14 ч. UTC

Печалби

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3.02.2026 г., 22:13 ч. UTC

Печалби

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3.02.2026 г., 22:12 ч. UTC

Печалби

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3.02.2026 г., 22:10 ч. UTC

Печалби

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3.02.2026 г., 22:10 ч. UTC

Печалби

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3.02.2026 г., 22:10 ч. UTC

Пазарно говорене

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3.02.2026 г., 22:10 ч. UTC

Печалби

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3.02.2026 г., 22:09 ч. UTC

Печалби

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3.02.2026 г., 22:09 ч. UTC

Печалби

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Сравнение с други в отрасъла

Ценова промяна

Xenon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

30.49% нагоре

12-месечна прогноза

Среден 54.09 USD 30.49%

Висок 62 USD

Нисък 44 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Xenon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Xenon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

34.81 / 38.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

152 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.